Allergen‐specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy
Authors:
- 28 September 2012
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 42 (12) , 1745-1755
Abstract
Summary: Background: Surrogate biomarkers of efficacy are needed in support of allergen‐specific immunotherapy.Objective: The aim of this study was to relate changes in peripheral CD4+ T cell responses to clinical efficacy during sublingual immunotherapy (SLIT).Methods: Allergen‐specific CD4+ T cell responses were assessed in peripheral blood mononuclear cells (PBMCs) from 89 grass pollen‐allergic individuals enrolled in a double‐blind placebo‐controlled SLIT study conducted in an allergen exposure chamber (ClinicalTrials.gov NCT00619827). Surface phenotype, proliferative responses, cytokine production and gene expression were analysed in coded samples at baseline, and after 2 and 4 months of SLIT, in PBMCs after in vitro allergen stimulation or among MHC class II/peptide (pMHCII)‐tetramer‐positive CD4+ T cells.Results: SLIT induced a 29.3% improvement of the average rhinoconjunctivitis total symptom score in the active group, when compared to the placebo group. In parallel, only minor changes in proportions of CD4+ T cells expressing Th1 (CCR5+, CXCR3+), Th2 (CRTh2+, CCR4+) and Treg (CD25+, CD127‐, Foxp3+) markers were detected. A down‐regulation of IL‐4 and IL‐10 gene expression and IL‐10 secretion (P < 0.001) were observed, as well as a decrease in the frequency of potential “pro‐allergic” CD27‐ Th2 cells from patients receiving active tablets (P < 0.001), but without any correlation with clinical benefit. pMHCII‐tetramer analyses failed to document any major impact in both numbers and polarization of circulating Phl p 1‐ and Phl p 5‐specific CD4+ T cells, confirming that early clinical improvement during SLIT is not associated with dramatic alterations in T lymphocyte responses.Conclusion & Clinical Relevance: Changes in patterns of peripheral CD4+ T cells are not markers for the early onset of efficacy during SLIT.Keywords
This publication has 37 references indexed in Scilit:
- Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapyJournal of Allergy and Clinical Immunology, 2012
- Hierarchical IL-5 Expression Defines a Subpopulation of Highly Differentiated Human Th2 CellsThe Journal of Immunology, 2011
- Ara h 1–reactive T cells in individuals with peanut allergyJournal of Allergy and Clinical Immunology, 2011
- Advances in mechanisms of asthma, allergy, and immunology in 2010Journal of Allergy and Clinical Immunology, 2011
- Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4The Journal of Immunology, 2010
- Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen‐specific CD4+ T cell responsesClinical & Experimental Allergy, 2010
- Allergen‐specific naïve and memory CD4+ T cells exhibit functional and phenotypic differences between individuals with or without allergyEuropean Journal of Immunology, 2010
- The Induced Regulatory T Cell Level, Defined as the Proportion of IL-10+Foxp3+ Cells among CD25+CD4+ Leukocytes, Is a Potential Therapeutic Biomarker for Sublingual Immunotherapy: A Preliminary ReportInternational Archives of Allergy and Immunology, 2010
- Specific Immunotherapy for Common Grass Pollen Allergies: Pertinence of a Five Grass Pollen VaccineInternational Archives of Allergy and Immunology, 2008
- Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1∗0101 tetramer-binding CD4+ T cellsJournal of Allergy and Clinical Immunology, 2006